In the IMpower133 trial, PD-L1 testing was not performed during screening for two main reasons: an expected high rate of inadequate samples and the previous results from the phase I trial that had not shown an association between SCLC response and PD-L1 expression (4, 13). This evidence concerns the gene CD274 and small cell lung carcinoma.